First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Time to Discontinuation on Darolutamide Longer in nmCRPC
Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.
mCRPC Treatment Landscape: Key Takeaways and Clinical Pearls
Expert oncologist Alicia Morgans, MD, MPH, shares her hope for future improvements in metastatic castration-resistant prostate cancer management as the landscape continues to evolve.
mCRPC: Practical Considerations for Real World Use of Lutetium Lu 177 Vipivotide Tetraxetan
Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.
Where Does Lutetium Lu 177 Vipivotide Tetraxetan Fit Into the mCRPC Treatment Landscape?
Key opinion leader Alicia Morgans, MD, MPH, considers the role of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management.
Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC: VISION and TheraP Trials
Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.
CARD Trial: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
Treatment Options for Patients With Metastatic Castration-Resistant Prostate Cancer
Following her review of a patient case of metastatic castration-resistant prostate cancer, Alicia Morgans, MD, MPH, highlights the range of treatment options in this setting.
A 75-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer
Expert oncologist Alicia Morgans, MD, MPH, shares details on the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.
Lutetium-PSMA-617 and Novel Agents in Prostate Cancer
Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Case 3: Metastatic Castrate-Resistant Prostate Cancer
Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
Therapy Sequencing and Patient Selection in Prostate Cancer Treatment
Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.
mCRPC: The TheraP Trial
A review of recent data from the TheraP trial.
Reviewing Data from the CARD Trial
Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.
Case 2: Metastatic Hormone-Sensitive Prostate Cancer
Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.
Radium-223 and the ALSYMPCA Trial
A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.
Lutetium-PSMA-617 for Prostate Cancer Treatment
A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.
PSMA-Positive mCRPC and the VISION Trial
Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.
Case 1: Metastatic Castrate-Resistant Prostate Cancer
Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
Defining PSMA-PET Scans for Prostate Cancer
Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.
Initial Risk Stratification of Localized Prostate Cancer
Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.
EP. 3B: Expert Perspective on the Changing Treatment Spectrum for Advanced Prostate Cancer
In this companion article, Alicia K. Morgans, MD, MPH, explains the role of androgen deprivation therapy, second-line options in the treatment of advanced prostate cancer, and methods of selecting appropriate treatment.
EP. 3A: Androgen Deprivation Therapy Failure and Second-Line Options in Advanced Prostate Cancer
In the third video of the series, Alicia K. Morgans, MD, MPH, of the Dana-Farber Cancer Institute sheds light on the rapidly developing treatment landscape for advanced prostate cancer.
Future Directions and Unmet Needs
Dr. Morgans discusses unmet needs and importance of including multidisciplinary teams when treating patients with mCRPC.
A review of the data from phase 3 randomized Phase 3 Study of 177Lu-PSMA-617 or best supportive/standard of care, VISION, in the treatment of patients with progressive PSMA-positive mCRPC and Dr. Morgans’ experience with 177Lu-PSMA-617.
Second-line and Beyond: Treatment of mCRPC
Dr. Morgans talks about available second-line treatment options for patients with mCRPC and considerations when choosing second and subsequent-line treatment options.
Follow-up and Monitoring
An overview of how patients with mCRPC are monitored and followed-up in practice and the triggers to reevaluate the treatment patient is receiving.
First-line Treatment Options for mCRPC
Dr. Morgans discusses first-line therapy options for mCRPC and her approach to deciding between different treatment options.
Case Overview: A 70-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
Alicia Morgans, MD, MPH presents the case of a 70-year-old man with progressive PSMA-positive mCRPC.
2 Commerce Drive Cranbury, NJ 08512